Cargando…

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C

BACKGROUND: Ribavirin (RBV) remains part of several interferon-free treatment strategies even though its mechanisms of action are still not fully understood. One hypothesis is that RBV increases responsiveness to type I interferons. Pegylated Interferon alpha (PEG-IFNa) has recently been shown to al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markova, Antoaneta A., Mihm, Ulrike, Schlaphoff, Verena, Lunemann, Sebastian, Filmann, Natalie, Bremer, Birgit, Berg, Thomas, Sarrazin, Christoph, Zeuzem, Stefan, Manns, Michael P., Cornberg, Markus, Herrmann, Eva, Wedemeyer, Heiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994015/ https://www.ncbi.nlm.nih.gov/pubmed/24751903 http://dx.doi.org/10.1371/journal.pone.0094512

Ejemplares similares

Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells
por: Schlaphoff, Verena, et al.
Publicado: (2011)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C
por: Owusu Sekyere, Solomon, et al.
Publicado: (2015)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
por: Wiegand, Steffen B., et al.
Publicado: (2015)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections
por: Malone, David F. G., et al.
Publicado: (2017)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
por: Atsukawa, Masanori, et al.
Publicado: (2013)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
por: Mücke, Marcus M., et al.
Publicado: (2019)

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
por: Murata, Kazumoto, et al.
Publicado: (2013)

Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment
por: Sidorkiewicz, Malgorzata, et al.
Publicado: (2020)

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study
por: Maasoumy, Benjamin, et al.
Publicado: (2017)

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin
por: Fujino, Tatsuya, et al.
Publicado: (2011)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
por: Heidrich, Benjamin, et al.
Publicado: (2014)

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
por: Wranke, Anika, et al.
Publicado: (2023)

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
por: Saadoun, David, et al.
Publicado: (2014)

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
por: Meyer, Manuela F, et al.
Publicado: (2007)

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population
por: Jin, Young-Joo, et al.
Publicado: (2013)

Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS
por: Stockhoff, Lena, et al.
Publicado: (2021)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Expert opinion on the treatment of patients with chronic hepatitis C
por: Zeuzem, S, et al.
Publicado: (2009)

Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
por: Maasoumy, Benjamin, et al.
Publicado: (2014)

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Nosocomial infections in female compared with male patients with decompensated liver cirrhosis
por: Griemsmann, Marie, et al.
Publicado: (2022)

Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial
por: Heidrich, Benjamin, et al.
Publicado: (2015)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
por: Jia, Zhifang, et al.
Publicado: (2012)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
por: Hofmann, Wolf Peter, et al.
Publicado: (2015)

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
por: Bhardwaj, Suvercha, et al.
Publicado: (2016)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

European vs. Egyptian HCV-4 Patients with Elevated Baseline HCV RNA, Treated with PEG-IFN-α2a and Ribavirin: The Role of Rapid and Early Virologic Response
por: Dimitroulopoulos, Dimitrios, et al.
Publicado: (2010)

Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ
por: Jud, Aurelia, et al.
Publicado: (2016)

Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells
por: Ochiai, Yushi, et al.
Publicado: (2020)

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
por: Hlaing, Naomi Khaing Than, et al.
Publicado: (2016)

HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial
por: Colombatto, P, et al.
Publicado: (2014)

Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun?
por: Tergast, T. L., et al.
Publicado: (2023)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis
por: Tergast, Tammo L., et al.
Publicado: (2023)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5eerk0re6e2fih9ug8icj12pco